Inclusion Criteria:

- Patients with histologically or cytologically confirmed clear cell metastatic RCC who
are eligible for cytoreductive nephrectomy.

- Patients must have measurable disease, defined as a lesion that can be accurately
measured in at least one dimension (longest diameter to be recorded) and measures
greater than or equal to 20 mm with conventional techniques or greater than or equal
to 10 mm with spiral CT scan. This does not include primary tumors, which will be
removed.

- ECOG performance status less than or equal to 1

- Female patients of childbearing potential (i.e. premenopausal, no hysterectomy) must
have a normal plasma beta human chorionic gonadotropin (bHCG) within 24 hours prior
to enrolling in the study due to the possible teratogenic effect. Patients with an
elevated bHCG will undergo appropriate evaluation to rule out pregnancy (i.e.
referral to Gyn service, pelvic ultrasound) and if pregnancy is ruled out and
elevated bHCG is determined to be of tumor origin, patients will be permitted to
proceed on study.

- Patients of child fathering or childbearing potential must agree to practice a form
of medically acceptable birth control while on study, i.e. condoms.

- Patients must give written informed consent prior to initiation of therapy, in
keeping with the policies of the institution. Patients with a history of major
psychiatric illness must be judged able to fully understand the investigational
nature of the study and the risks associated with the therapy. The only approved
consent is attached to this protocol.

- Patients must have ability to comply with study and/or follow-up procedures.

- Patients must have adequate organ and marrow function within 14 days as defined
below: absolute neutrophil count >/=1,500/micro platelets >/= 75,000/micro Hgb > 9.0
g/dL (may be transfused or receive epoetin alfa permitted) total bilirubin mg/dL albumin > 3.0 g/dL serum creatinine metastases present.

Exclusion Criteria:

- Patients must not have organ allografts.

- Patients must not have had major surgical procedure, open biopsy, or significant
traumatic injury within 28 days prior to Day 0, or anticipation of need for major
surgical procedure during the course of the study (other than defined by protocol);
or fine needle aspirations or core biopsies within 7 days prior to Day 0.

- No prior malignancy is allowed, except for non-melanoma skin cancer, in situ
carcinoma of any site, or other cancers for which the patient has been adequately
treated and disease free for 5 years.

- Patients must not have received any systemic anticancer therapy. Radiation therapy is
allowed if >/= 2 weeks from study drug administration.

- Patients must not be scheduled to receive another experimental drug while on this
study. Patients are permitted to be on concomitant bisphosphonates and megestrol
acetate.

- Patients must not have a primary brain tumor (excluding meningiomas other benign
lesions), any brain metastases, leptomeningeal disease, seizure disorders not
controlled with standard medical therapy, or history of stroke within the past 5
years.

- History of serious systemic disease, including myocardial infarction or unstable
angina within the last 12 months, history of hypertensive crisis or hypertensive
encephalopathy, uncontrolled hypertension (blood pressure of >140/90 mmHg on
medication), New York Heart Association (NYHA) Grade II or greater congestive heart
failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic
atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular
tachycardia are eligible), significant vascular disease or symptomatic peripheral
vascular disease.

- Patients must not have history of other diseases, metabolic dysfunction, physical
examination finding, or clinical laboratory finding giving reasonable suspicion of a
disease or condition that contraindicates the use of an investigational drug or that
might affect the interpretation of the results of the study or render the subject at
high risk from treatment complications.

- Patients receiving any concomitant systemic therapy for renal cell cancer are
excluded, but patients taking bisphosphonates and megestrol acetate are not excluded.

- Patients must not require total parenteral nutrition with lipids.

- Patients must not have significant proteinuria at baseline. Patients who are
unexpectedly discovered to have greater than or equal to 1+ proteinuria on routine
urinalysis at baseline should undergo a 24 hour urine collection, which must be an
adequate collection and must demonstrate less than or equal to 1g of protein/24 hr to
allow participation in the study.

- Patients must not have clinical history of coagulopathy, bleeding diathesis or
thrombosis.

- Patients must not have a serious, nonhealing wound, ulcer, or bone fracture.

- Pregnancy (positive pregnancy test) or lactation.

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment.

- Know hypersensitivity to any component of bevacizumab.